Introduction
Ductal adenocarcinoma of the prostate (PDA) is a rare histological subtype, accounting for only 1-5% of all prostate cancers (PCa). It was initially described by Melicow and Pacher in 1967 (1) .
Histologically, it is characterized by the presence of tall, pseudostratified columnar epithelium with abundant cytoplasm organized in a papillary or cribriform-papillary pattern. It can occur as a pure form or, more often, mixed with the typical adenocarcinoma pattern. With respect to histology, it has two growth patterns: type A, an exuberant papillary en-patients with this subtype of tumour (5, 6) . Finally, the rarity of this tumour forced to base our knowledge on small case series or on individual case reports and do not help to establish appropriate guidelines. In fact, some aspects of this cancer are still unclear and insufficient data are available regarding its response to conventional therapies especially after biochemical recurrence. Therefore, its management does not differ from that of the well-known AA, although the diagnosis of this tumour masks clinical implications that are not still well understood.
This report presents a description of clinical management and therapy response of a pure PDA case in a patient with malignancy recurrence after radical prostatectomy.
Discussion
A 69-year-old Caucasian man presented in our Department in February 2011 with an elevated PSA value (6.3 ng/ml) and obstructive urinary symptoms in the form of increased urgency and nocturia. Informed consent for scientific divulgation of data was obtained before all procedures. Digital rectal examination (DRE) was negative for prostate nodules. He did a 20 cores transrectal ultrasound-guided (TRUS) biopsy. This examination revealed a Gleason Score 8 (4 + 4) PDA in 10/20 cores. The remaining 10/20 cores were cancer free. Initial bone scan and abdominal computed tomography (CT) were negative for metastatic disease. The radical prostatectomy and bilateral pelvic lymph node dissection (totally 11 L.Ns for right side and 8 L.Ns for left side) was performed.
Histopathology examination confirmed the presence of a pure Gleason score 8 (4 + 4) prostate confined PDA without nodal metastasis (pT2c N0 Mx Gleason 8 R0) ( Fig. 1 ). Two months later, PSA value was 0.01 ng/ml, but it increases in the checks carried out 3, 6 and 8 months later (0.02, 0.29 and 1.36 ng/ml, respectively) ( Fig. 2 ). The patient underwent PET-CT 11-choline to identify local or distant recurrences of the disease. The PET-CT scan identified two pulmonary nodules (approximately 1 cm) with a tracer uptake (apical segment of right lower lung lobe and anterior segment of left apical lung lobe) ( Fig. 3A) .
Therefore, we took the decision to perform CT-guided biopsy of the lung nodules to assess a histological confirmation of distant recurrent PDA and to exclude a primitive lung tumour (alveolar bronchiolar carcinomas can pick up choline). This examination confirmed the presence of metastatic PCa positive for PSA. Thus, the patient started hormonal therapy with LH-RH analogue (triptorelin pamoate 11.25) converted in major androgenic bloc (MAB) 6 months later (leuprolelin acetate 22.5 mg and bicalutamide 50 mg) for the partial response of disease (PSA decreased to 0.02 ng/ml, but after 3 months, it starts to arise again becoming 0.3 ng/ml in the following 6 months). Eight months later, no control of disease was obtained (PSA was still raising up 2 ng/ml) ( Fig. 2) . We took the decision to repeat a PET-CT scan ( Fig. 3B ) that showed an incongruity between the PSA level and the important progression of disease (significant increase of all known lesions, onset of a new VIII left rib metastasis and development of a new nodal mass with intense uptake of choline in left lung hilum). These findings preceded the slowly subsequent increase of PSA value in the following 10 months. Therefore, when PSA became 7.34 ng/ml, we took the decision to perform six cycles of chemotherapy with 3-weekly Taxotere (Docetaxel®) 75 mg/m 2 along with prednisolone 5 mg twice-daily scheme. Close follow-up demonstrated a relative stability of the disease during chemotherapy based on PSA level (Fig. 2) , but a new PET-CT was performed with evidence of a further progression of all known previous lesions aggravated by development of multiple (at least 10 new lesions) bilateral lung metastases (Fig. 3C ). According with these findings, the decision was to switch chemotherapy to VII cycles of Abiraterone acetate (Zytiga®) 1000 mg daily administration, but no significant response was observed and the PSA value increased until 27.98 ng/ml in the following 5 months (Fig. 2) . One month later, PSA raised up to 150 ng/ml. A new radiological valuation showed a further progression of metastatic disease and the patient died some weeks later.
This case is emblematic of the variable and unpredictable behaviour of this rare histological type of PCa. The evidence of pulmonary metastases with an initial organ-confined prostate cancer after prostatectomy (negative resection margins without evidence of lymph node and bone metastases) may suggest a different natural course of PDA. A review of the literature revealed that visceral (lung and liver) metastases were relatively common in PDA compared with usual prostate AA (3). PDA may have the propensity to haematogenous spread rather than lymphatic in contrast to purely AA variant. In our opinion, this should be related to the histopathological growth pattern and to the anatomic distribution of cancer within the gland. The development into glandular ducts, rather than inside the glandular berry, could facilitate direct vascular invasion instead of involvement of the glandular interstice or of the periacinar lymphatic vessels.
Even though PDA cell produces PSA, the serum concentration of this marker is not elevated in all patients. Morgan et al (7) stated that a number of patients with PDA should have PSA level less than 4.0 ng/ml at the diagnosis. Therefore, PDA is less likely detectable based only on PSA serum level. On the basis of these evidences, the common tools used for the diagnosis, staging and follow-up of PCa may not have the same validity for this tumour subtype. Some Authors suggest adopting other alternative markers such as carcinoembryonic antigen (CEA); however, the small number of reported cases limits the significance of this observation (5) . Considering the above reasons, we think that a contemporary and steady radiological examination should be useful to manage this tumour. PET-CT scan plays, in this experience, a role of particular importance in the disclosure of metastasis progression and its therapeutic management. Although the PSA serum values were in steady slight increase, PET-CT scan showed a faster progression of the recurred disease (faster increase of volume and activity of mediastinal lesions and metastatic involvement on other sites). Thus, in our opinion, a radiological examination is necessary because it should help urologist to establish, with more precision, the appropriate timing for therapeutic decisions. Moreover, it is possible that the cancer had already given unrecognized lung metastases at primary tumour diagnosis. PET-CT scan (performed preoperatively) gives a reliable total body examination and could improve the diagnosis of metastases not revealed using routinely tests recommended for PCa staging (i.e. abdomen CT and bone scan).
Finally, the PDA response to hormone therapy is still debatable showing controversial statements. Millar et al. found an excellent and long-term response (mean 5.4 years) to the endocrine control based on PSA level (8) . In our experience, hormone therapy does not give an adequate control of disease. The PSA trend during hormonal therapy, in our case, might suggest the presence of a primitive castrationresistant cancer or a fast hormonal escape conversion of the tumour (Fig. 2) . Moreover, the PET-CT showed a rapid disease progression that was unexpected considering the PSA value alone.
In a case report, Aalok et al (9) underline, for the first time, as the chemotherapy (taxotere 75 mg along with prednisone 5 mg daily scheme), quickly adopted after biochemical recurrence, assured the control of a PDA metastatic disease for more than 27 months (reduction of imaging findings and of the PSA level). Unfortunately, no other data are available to compare these results. In our experience, the same chemotherapy scheme showed only a 5 months partial control of PSA level (ranged from 7.5 to 9.5 ng/ml) not confirmed by PET-CT findings (progression of all known previous findings aggravated by development of multiple bilateral lung metastases).
Edgar Linden-Castro et al. (10) , for the first time, observed that a patient treated with Abiraterone acetate 1000 mg had a PSA progression time of 9 months and radiographic progression-free survival of 11 months. In our experience, Abiraterone acetate did not stop the progression of the PSA, which recorded a new peak of increase up to 27 ng/ml. Unfortunately, a new radiological evidence is not still available, but we can expect a new important disease progression.
Summarizing, in our experience, the available therapies used for metastatic PCa treatment seem to slow down but not to stop the disease progression of PDA with a survival after recurrence of about 45 months (significantly less if compared with a Gl 8 typical AA). Probably, some histological characteristics (pure or mixed, growth pattern Type A or Type B) or other still unknown factors may affect the tumour response to therapy and explain the differences between our findings and those of other cases. So, more efforts are required to add new knowledge about the biology of this tumour and assess what is known until now.
Conclusion
Our findings confirm that PDA is a more aggressive variant of PCa. PSA may be an insufficient marker for disease management and a partial or complete PSA response to therapy does not necessarily mean lack of disease progression. New markers or radiological evaluation should be applied to improve the management of this aggressive variant and, in our experience, PET -CT scan has proved to be particularly useful. We observed that the available cures seem to slow down but not stop the disease progression. Probably, some histological characteristics or other still unknown factors may affect the tumour response to therapy. More efforts are required to add new knowledge about the biology of this tumour and assess what is known until now.
